MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that immunomodulatory drugs (IMiDs) exert anti-MM activity via destabilization of MCT1 and CD147. In this study, cell samples of 654 patients with MM who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroh, Jacob, Seckinger, Anja, Heider, Michael, Rudelius, Martina, Eichner, Ruth, Schick, Markus, Slawska, Jolanta, Emde-Rajaratnam, Martina, Salwender, Hans, Bertsch, Uta, Goldschmidt, Hartmut, Weisel, Katja, Scheid, Christof, Keller, Ulrich, Hose, Dirk, Bassermann, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791591/
https://www.ncbi.nlm.nih.gov/pubmed/34768284
http://dx.doi.org/10.1182/bloodadvances.2021005532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791591/
https://www.ncbi.nlm.nih.gov/pubmed/34768284
http://dx.doi.org/10.1182/bloodadvances.2021005532

Ejemplares similares